Insider Selling: CryoPort (NASDAQ:CYRX) Insider Sells $486,192.00 in Stock

CryoPort, Inc. (NASDAQ:CYRX) insider Edward Zecchini sold 33,600 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $14.47, for a total transaction of $486,192.00. Following the transaction, the insider directly owned 109,719 shares of the company’s stock, valued at $1,587,633.93. This represents a 23.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

CryoPort Stock Performance

CYRX traded up $0.24 during trading on Friday, reaching $14.62. The company’s stock had a trading volume of 502,102 shares, compared to its average volume of 554,117. CryoPort, Inc. has a 52-week low of $6.16 and a 52-week high of $16.73. The company’s fifty day moving average price is $12.30 and its 200-day moving average price is $10.30. The company has a market capitalization of $736.85 million, a price-to-earnings ratio of 10.83 and a beta of 1.90.

CryoPort (NASDAQ:CYRX) last released its earnings results on Monday, May 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The business had revenue of $47.80 million for the quarter, compared to analyst estimates of $44.86 million. Equities analysts predict that CryoPort, Inc. will post -0.85 earnings per share for the current year.

Hedge Funds Weigh In On CryoPort

A number of large investors have recently made changes to their positions in CYRX. AQR Capital Management LLC increased its stake in shares of CryoPort by 285.5% during the 1st quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock worth $1,597,000 after purchasing an additional 194,482 shares in the last quarter. Creative Planning purchased a new stake in CryoPort in the 2nd quarter valued at approximately $96,000. Rhumbline Advisers grew its holdings in CryoPort by 17.6% during the 2nd quarter. Rhumbline Advisers now owns 92,098 shares of the company’s stock valued at $687,000 after buying an additional 13,778 shares during the last quarter. American Century Companies Inc. increased its position in CryoPort by 24.4% during the second quarter. American Century Companies Inc. now owns 88,876 shares of the company’s stock worth $663,000 after buying an additional 17,459 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new position in CryoPort during the second quarter worth $254,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Wall Street Analyst Weigh In

CYRX has been the topic of several recent analyst reports. KeyCorp boosted their target price on CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. BTIG Research boosted their target price on CryoPort from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Wall Street Zen upgraded CryoPort from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Needham & Company LLC increased their price target on shares of CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Jefferies Financial Group set a $13.50 price target on shares of CryoPort in a report on Monday. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.11.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.